Información del artículo
Después de una breve introducción sobre el sistema renina-angiotensinaaldosterona, se resaltan las circunstancias tanto fisiológicas como patológicas que modifican el sistema, así como también los fármacos que estimulan e inhiben la secreción de renina y aldosterona, que servirán al lector de guía para la interpretación de los resultados. La utilidad clínica de la determinación de la actividad renina plasmática (ARP) y la aldosterona se centra en el diagnóstico de algunas hipertensiones secundarias (hipertensión vasculorrenal, tumores secretantes de renina, hipermineralocorticismos y ciertas tubulopatías hereditarias infrecuentes), para el estudio de las alteraciones del metabolismo del potasio (hipo e hiperpotasemia), y para la evaluación pronóstica y/o terapéutica de ciertos estados edematosos (cirrosis hepática y syndrome nefrótico).
Palabras clave:
Sistema renina-angiotensina-aldosterona
Actividad renina plasmática
Hipertensión arterial secundaria
After a brief introduction on the renin-angiotensin-aldosterone system, the article analyses the physiological and pathological circumstances which modify it, and the drugs which stimulate or inhibit the release of rennin and aldosterone. This analysis is intended as a guide to interpret results.
In order to establish the medical effectiveness of determining the plasmatic renin activity (PRA) and the aldosterone, the article focuses on the diagnosis of some secondary hypertensions (vascularrenal hypertension, renin releasing tumours, hypermineralcorticisms and certain infrequent hereditary tubular pathologies), on the analysis of the alterations of potassium metabolism (hypo- and hyperpotassaemia), and on the prognostic and therapeutic evaluation of certain oedematous states (cirrhosis of the liver and nephritic syndrome).
Key words:
Renin-angiotensin-aldosterone system
Plasmatic renin activity
Secondary hypertension
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Schnermann, J.P. Briggs.
The macula densa is worth its salt.
J Clin Invest, 104 (1999), pp. 1007-1009
[3.]
D.M. Wilson, J.A. Luetscher.
Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus.
N Engl J Med, 323 (1990), pp. 1101-1106
[4.]
J.E. Sealey, N. Von Lutterotti, S. Rubattu, W.G. Campbell Jr, F. Gahnem, J.M. Halimi, et al.
The greater renin system. Its prorenindirected vasodilator limb. Relevance to diabetes mellitus, pregnancy, and hypertension.
Am J Hypertens, 4 (1991), pp. 972-977
[5.]
A.R. Brasier, J. Li.
Mechanisms for inducible control of angiotensinogen gene transcription.
Hypertension, 27 (1996), pp. 465-475
[6.]
T. Unger, J. Li.
The role of the renin-angiotensin-aldosterone system in heart failure.
J Renin Angiotensin Aldosterone Syst, 5 (2004), pp. S7-S10
[7.]
C.C. Wei, Q.C. Meng, R. Palmer, G.R. Hageman, J. Durand, W.E. Bradley, et al.
Evidence for angiotensin-converting enzymeand chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo.
Circulation, 99 (1999), pp. 2583-2589
[8.]
M.C. Lansang, R. Stevanovic, D.A. Price, L.M. Laffel, N.K. Hollenberg.
ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus.
Kidney Int, 67 (2005), pp. 1033-1037
[9.]
S. Takai, D. Jin, M. Muramatsu, Y. Okamoto, M. Miyazaki.
Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis.
Eur J Pharmacol, 501 (2004), pp. 1-8
[10.]
V. Richard, S. Hurel-Merle, E. Scalbert, G. Ferry, F. Lallemand, J.P. Bessou, et al.
Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries.
Circulation, 104 (2001), pp. 750-752
[11.]
C.I. Johnston, M. Naitoh, L.M. Burrell.
Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues.
J Hypertens Suppl, 15 (1997), pp. S3-S6
[12.]
R. Ardaillou, D. Chansel.
Synthesis and effects of active fragments of angiotensin II.
Kidney Int, 52 (1997), pp. 1458-1468
[13.]
C.M. Ferrario, M.C. Chappell, E.A. Tallant, K.B. Brosnihan, D.I. Diz.
Counterregulatory actions of angiotensin-(1-7).
Hypertension, 30 (1997), pp. 535-541
[14.]
M.W. Taal, B.M. Brenner.
Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
Kidney Int, 57 (2000), pp. 1803-1817
[15.]
J.A. Delyani.
Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.
Kidney Int, 57 (2000), pp. 1408-1411
[16.]
V. Robert, C. Heymes, J.S. Silvestre, A. Sabri, B. Swynghedauw, C. Delcayre.
Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis.
Hypertension, 33 (1999), pp. 981-986
[17.]
R.M. Carey, Z.Q. Wang, H.M. Siragy.
Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function.
Hypertension, 35 (2000), pp. 155-163
[18.]
T. Unger, O. Chung, T. Csikos, J. Culman, S. Gallinat, P. Gohlke, et al.
Angiotensin receptors.
J Hypertens Suppl, 14 (1996), pp. S95-S103
[19.]
T. Yang, J.M. Park, L. Arend, Y. Huang, R. Topaloglu, A. Pasumarthy, et al.
Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line.
J Biol Chem, 275 (2000), pp. 37922-37929
[20.]
G.F. DiBona.
Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function.
Hypertension, 36 (2000), pp. 1083-1088
[21.]
W.L. Henrich.
Role of prostaglandins in renin secretion.
Kidney Int, 19 (1981), pp. 822-830
[22.]
J.M. Smith, D.R. Mouw, A.J. Vander.
Effect of parathyroid hormone on plasma renin activity and sodium excretion.
Am J Physiol, 236 (1979), pp. F311-F319
[23.]
A. Kurtz, B.R. Della, J. Pfeilschifter, R. Taugner, C. Bauer.
Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process.
Proc Natl Acad Sci USA, 83 (1986), pp. 4769-4773
[24.]
E. Hackenthal, M. Paul, D. Ganten, R. Taugner.
Morphology, physiology, and molecular biology of renin secretion.
Physiol Rev, 70 (1990), pp. 1067-1116
[25.]
P. Fredlund, S. Saltman, T. Kondo, J. Douglas, K.J. Catt.
Aldosterone production by isolated glomerulosa cells: modulation of sensitivity to angiotensin II and ACTH by extracellular potassium concentration.
Endocrinology, 100 (1977), pp. 481-486
[26.]
L.G. Palmer, G. Frindt.
Aldosterone and potassium secretion by the cortical collecting duct.
Kidney Int, 57 (2000), pp. 1324-1328
[27.]
X.L. Chen, D.A. Bayliss, R.J. Fern, P.Q. Barrett.
A role for T-type Ca2+ channels in the synergistic control of aldosterone production by ANG II and K+.
Am J Physiol, 276 (1999), pp. F674-F683
[28.]
B.A. Clark, R.S. Brown, F.H. Epstein.
Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion: potential relevance to hypoaldosteronism in man.
J Clin Endocrinol Metab, 75 (1992), pp. 399-403
[29.]
M.H. Maxwell, M.R. Rudnick, A.U. Waks.
New approaches to the diagnosis of renovascular hypertension.
Adv Nephrol Necker Hosp, 14 (1985), pp. 285-304
[31.]
G.B. Vasbinder, P.J. Nelemans, A.G. Kessels, A.A. Kroon, P.W. De Leeuw, J.M. Van Engelshoven.
Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis.
Ann Intern Med, 135 (2001), pp. 401-411
[32.]
W. Bischoff, W. Pohle, U. Goerttler.
Treatment of arteriovenous angiomas of the kidney: surgical intervention and intra-arterial embolization.
J Urol, 122 (1979), pp. 825-828
[33.]
G.P. Rossi, M. Cesari, M. Chiesura-Corona, D. Miotto, A. Semplicini, A.C. Pessina.
Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery.
J Hypertens, 20 (2002), pp. 975-984
[34.]
F. Haab, J.M. Duclos, T. Guyenne, P.F. Plouin, P. Corvol.
Renin secreting tumors: diagnosis, conservative surgical approach and long-term results.
J Urol, 153 (1995), pp. 1781-1784
[35.]
M.R. Moein, V.O. Dehghani.
Hypertension: a rare presentation of renal cell carcinoma.
J Urol, 164 (2000), pp. 2019
[36.]
P. Corvol, F. Pinet, P.F. Plouin, P. Bruneval, J. Menard.
Renin-secreting tumors.
Endocrinol Metab Clin North Am, 23 (1994), pp. 255-270
[37.]
P.M. Stewart.
Mineralocorticoid hypertension.
Lancet, 353 (1999), pp. 1341-1347
[38.]
M. Stowasser.
Primary aldosteronism: revival of a syndrome.
J Hypertens, 19 (2001), pp. 363-366
[39.]
N.M. Kaplan.
Cautions over the current epidemic of primary aldosteronism.
Lancet, 357 (2001), pp. 953-954
[40.]
T.J. McKenna, S.J. Sequeira, A. Heffernan, J. Chambers, S. Cunningham.
Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism.
J Clin Endocrinol Metab, 73 (1991), pp. 952-957
[41.]
V.M. Montori, G.L. Schwartz, A.B. Chapman, E. Boerwinkle, S.T. Turner.
Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.
Mayo Clin Proc, 76 (2001), pp. 877-882
[42.]
O.B. Holland, H. Brown, L. Kuhnert, C. Fairchild, M. Risk, C.E. Gómez- Sánchez.
Further evaluation of saline infusion for the diagnosis of primary aldosteronism.
Hypertension, 6 (1984), pp. 717-723
[43.]
G.P. Rossi, A. Sacchetto, P. Visentin, C. Canali, G.R. Graniero, P. Palatini, et al.
Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.
Hypertension, 27 (1996), pp. 1039-1045
[44.]
J.L. Phillips, M.M. Walther, J.C. Pezzullo, W. Rayford, P.L. Choyke, A.A. Berman, et al.
Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma.
J Clin Endocrinol Metab, 85 (2000), pp. 4526-4533
[45.]
G.P. Rossi, A. Sacchetto, M. Chiesura-Corona, R. De Toni, M. Gallina, G.P. Feltrin, et al.
Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases.
J Clin Endocrinol Metab, 86 (2001), pp. 1083-1090
[46.]
R.P. Lifton, R.G. Dluhy, M. Powers, G.M. Rich, M. Gutkin, F. Fallo, et al.
Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase.
Nat Genet, 2 (1992), pp. 66-74
[47.]
R.G. Dluhy, R.P. Lifton.
Glucocorticoid-remediable aldosteronism.
J Clin Endocrinol Metab, 84 (1999), pp. 4341-4344
[48.]
P. Ferrari, E. Lovati, F.J. Frey.
The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
J Hypertens, 18 (2000), pp. 241-248
[49.]
J. Guo, M.M. Reidenberg.
Inhibition of 11beta-hydroxysteroid dehydrogenase by bioflavonoids and their interaction with furosemide and gossypol.
J Lab Clin Med, 132 (1998), pp. 32-38
[51.]
D.S. Geller, A. Farhi, N. Pinkerton, M. Fradley, M. Moritz, A. Spitzer, et al.
Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.
Science, 289 (2000), pp. 119-123
[52.]
Y. Yamashita, M. Koga, Y. Takeda, N. Enomoto, S. Uchida, K. Hashimoto, et al.
Two sporadic cases of Liddle's syndrome caused by de novo ENaC mutations.
Am J Kidney Dis, 37 (2001), pp. 499-504
[53.]
S.C. Reinalter, N. Jeck, C. Brochhausen, B. Watzer, R.M. Nusing, H.W. Seyberth, et al.
Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
Kidney Int, 62 (2002), pp. 253-260
[54.]
I. Zelikovic, R. Szargel, A. Hawash, V. Labay, I. Hatib, N. Cohen, et al.
A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes.
Kidney Int, 63 (2003), pp. 24-32
[55.]
J.M. Achard, S. Disse-Nicodeme, B. Fiquet-Kempf, X. Jeunemaitre.
Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome).
Clin Exp Pharmacol Physiol, 28 (2001), pp. 1048-1052
[56.]
P. Sartorato, Y. Khaldi, A.L. Lapeyraque, D. Armanini, U. Kuhnle, R. Salomon, et al.
Inactivating mutations of the mineralocorticoid receptor in type I pseudohypoaldosteronism.
Mol Cell Endocrinol, 217 (2004), pp. 119-125
[57.]
E. Hummler.
Epithelial sodium channel, salt intake, and hypertension.
Curr Hypertens Rep, 5 (2003), pp. 11-18
[58.]
R.A. DeFronzo.
Hyperkalemia and hyporeninemic hypoaldosteronism.
Kidney Int, 17 (1980), pp. 118-134
[59.]
M.W. Davenport, R.D. Zipser.
Association of hypotension with hyperreninemic hypoaldosteronism in the critically ill patient.
Arch Intern Med, 143 (1983), pp. 735-737
[60.]
R.W. Schrier, W.T. Abraham.
Hormones and hemodynamics in heart failure.
N Engl J Med, 341 (1999), pp. 577-585
[61.]
A. Kjaer, B. Hesse.
Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.
Clin Physiol, 21 (2001), pp. 661-672
[62.]
A.L. Gerbes, H. Wernze, R.M. Arendt, A. Riedel, T. Sauerbruch, G. Paumgartner.
Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis.
Hepatology, 9 (1989), pp. 417-422
[63.]
V. Arroyo, J. Bosch, J. Gaya-Beltran, D. Kravetz, L. Estrada, F. Rivera, et al.
Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites.
Ann Intern Med, 94 (1981), pp. 198-201
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición